cbdMD Inc. (YCBD) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, YCBD scores 37 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 5 of 20 (ROIC -30.4%; FCF yield 0%), indicating the business is not currently generating returns on invested capital or free cash flow to support value. Whale 13F flow scores 10 of 20 (institutional accumulation and options positioning), a moderate reading that does not offset the weak fundamentals. Insider conviction scores 5 of 20 (SEC Form 4 and Congressional PTR cluster flow), signaling limited insider-backed confidence. Macro regime fit scores 7 of 20 (Beta 1.0; sector sensitivity), meaning the stock tracks the market without a clear macro edge. Forensic balance sheet scores 10 of 20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.5), a middling reading that points to financial fragility rather than distress.

For a prospective investor, the upside case rests on the price moving sharply higher on liquidity-driven flows and on any operational turnaround, but the source data contains no evidence of earnings or cash generation to anchor a valuation. Valuation multiples (P/E, EV/EBITDA) are unavailable, so the tradeoff cannot be measured against earnings. The primary risk is that negative returns and cash burn persist, leaving the equity dependent on external financing or flow-driven price action rather than fundamentals.

Per the SEC financials, the company reported net losses in each period shown, with operating margin at -11.3% and net margin at -10.6%, alongside a gross margin of 62.4%. Revenue declined from $24.2M in FY 2023 to $19.5M in FY 2024 and $19.2M in FY 2025. Per the Roarable RQD rating, ROIC is -30.4%, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Reported cash was $3.4M in FY 2025, up from $2.0M in FY 2024, while free cash flow remained negative in all periods shown.

Per the recent news wire, the key catalysts are the completed acquisition of the operating assets and brands of Twinlab, including Reserveage and Metabolife, framed as an expansion into broader wellness, and the ABC Stores distribution expansion into Hawaii and beyond. Additional items include a National Pet CBD Month communication and a sector-level stock analysis report. All news items are rated YELLOW with MARKET WIRE impact labels, indicating no high-severity flag in the feed itself. Per the Butterfly Supply-Chain Graph, a LIQUIDITY_TAILWIND signal is bullish with severity 94 and a MACRO TAILWIND SCORE of 96/100, attributing a 4.17x True Net Liquidity elasticity and a -0.16 correlation to the stock, with the Net Liquidity index at $5,745.73B and a -0.64% 4-week rate of change. The key risk watch item is that this macro signal conflicts with the weak fundamental pillars in the RQD rating, so liquidity-driven price action may not persist if cash generation does not improve.

• What are the Net Income and Operating Income trends beyond FY 2023–FY 2025, and what is the basis for the company's path to profitability?
• What is the debt balance, since the financials report debt as N/A and Debt/Equity is given only as 0.5?
• How does the Twinlab acquisition affect revenue, margins, and cash burn, given the source does not quantify its financial impact?
• What are the EPS and valuation multiples (P/E, EV/EBITDA), which are unavailable and prevent a valuation comparison?
• What institutional holdings, 13F positions, and insider Form 4 activity exist, since the holders section is empty?